πŸ‡ΊπŸ‡Έ FDA
Patent

US 10278977

Methods for treating hypersomnolence

granted A61KA61K31/015A61K31/04

Quick answer

US patent 10278977 (Methods for treating hypersomnolence) held by Umecrine Cognition AB expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Umecrine Cognition AB
Grant date
Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/015, A61K31/04, A61K31/568